NASDAQ:NEOS - Neos Therapeutics Stock Price, Forecast & News

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

Neos Therapeutics Inc (NASDAQ:NEOS) announced its quarterly earnings results on Friday, November, 8th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.07. The firm earned $17.54 million during the quarter. Neos Therapeutics had a negative net margin of 35.77% and a negative return on equity of 2,087.24%. View Neos Therapeutics' Earnings History.

Neos Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Neos Therapeutics.

2 Wall Street analysts have issued twelve-month price objectives for Neos Therapeutics' shares. Their forecasts range from $3.00 to $10.00. On average, they anticipate Neos Therapeutics' stock price to reach $6.50 in the next year. This suggests a possible upside of 306.3% from the stock's current price. View Analyst Price Targets for Neos Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neos Therapeutics.

News headlines about NEOS stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Neos Therapeutics earned a news impact score of 0.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Neos Therapeutics.

Neos Therapeutics saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 2,160,000 shares, an increase of 10.8% from the November 28th total of 1,950,000 shares. Based on an average trading volume of 173,400 shares, the days-to-cover ratio is currently 12.5 days. Currently, 4.4% of the shares of the company are sold short. View Neos Therapeutics' Current Options Chain.

Some companies that are related to Neos Therapeutics include MannKind (MNKD), VBI Vaccines (VBIV), Avadel Pharmaceuticals (AVDL), MediciNova (MNOV), Evofem Biosciences (EVFM), Satsuma Pharmaceuticals (STSA), Geron (GERN), IVERIC bio (ISEE), BioXcel Therapeutics (BTAI), Wave Life Sciences (WVE), Kamada (KMDA), Sol Gel Technologies (SLGL), Osmotica Pharmaceuticals (OSMT), BIOFRONTERA AG/ADR (BFRA) and Concert Pharmaceuticals (CNCE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Fibrocell Science (FCSC), Exelixis (EXEL), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), Verastem (VSTM), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Amicus Therapeutics (FOLD), Melinta Therapeutics (MLNT) and BioDelivery Sciences International (BDSI).

(NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEOS stock can currently be purchased for approximately $1.60.

Neos Therapeutics has a market capitalization of $79.57 million and generates $49.99 million in revenue each year. The company earns $-51,670,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Neos Therapeutics employs 215 workers across the globe.View Additional Information About Neos Therapeutics.

The official website for Neos Therapeutics is http://www.neostx.com/.

Neos Therapeutics' mailing address is 2940 N. HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]